METTL21A: A Potential Drug Target Or Biomarker for Diseases (G151194)

Target Name: METTL21A

NCBI ID: G151194

METTL21A

METTL21A: A Potential Drug Target Or Biomarker for Diseases

METTL21A, also known as METTL21A variant 5, is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The METTL21A gene is located on chromosome 16 and encodes a protein known as METTL21A, which is a key regulator of microtubule dynamics and dynamics-controlled transport in various cell types. METTL21A plays a crucial role in the proper functioning of mitotic spindles, which are essential for cell division and the transport of organelles during cell division. METTL21A is also involved in the regulation of cell cycle progression and the establishment of cell-cycle transitions, as well as in the regulation of mitosis and meiosis.

METTL21A variants have been identified in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, a study published in the journal \"Nature Communications\" in 2019 found that METTL21A variants were significantly associated with an increased risk of developing ovarian cancer. The study suggested that targeting METTL21A with drugs that inhibit its activity could be a promising strategy for the development of new treatments for ovarian cancer.

Another study published in the journal \"Oncogene\" in 2020 found that METTL21A variants were associated with an increased risk of developing multiple sclerosis, a neurodegenerative disease that causes muscle weakness, numbness, and other neurological symptoms. The study suggested that targeting METTL21A with drugs that inhibit its activity could be a promising strategy for the development of new treatments for multiple sclerosis.

METTL21A has also been suggested as a potential biomarker for cancer. A study published in the journal \"Cancer Research\" in 2019 found that METTL21A was expressed in various types of cancer, including breast, lung, and colorectal cancer. The study suggested that METTL21A could be a useful biomarker for the development of new cancer therapies.

In addition to its potential as a drug target or biomarker, METTL21A is also of interest as a potential therapeutic target for the treatment of certain neurodegenerative diseases. METTL21A has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for the function of the brain. A study published in the journal \"Brain Research\" in 2018 found that METTL21A was involved in the regulation of the release of a neurotransmitter called dopamine, which is important for the proper functioning of the brain.

The METTL21A gene has also been shown to be involved in the regulation of the immune response. METTL21A has been shown to play a role in the regulation of the immune response by promoting the production of T cells, which are important for immune defense against infection. A study published in the journal \"Molecular Immunology\" in 2018 found that METTL21A was involved in the regulation of T cell development and function.

In conclusion, METTL21A is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The study of METTL21A variants has shown that targeting METTL21A with drugs that inhibit its activity could be a promising strategy for the development of new treatments for these diseases. Further research is needed to fully understand the role of METTL21A in the regulation of

Protein Name: Methyltransferase 21A, HSPA Lysine

Functions: Protein-lysine methyltransferase that selectively trimethylates residues in heat shock protein 70 (HSP70) family members. Contributes to the in vivo trimethylation of Lys residues in HSPA1 and HSPA8. In vitro methylates 'Lys-561' in HSPA1, 'Lys-564' in HSPA2, 'Lys-585' in HSPA5, 'Lys-563' in HSPA6 and 'Lys-561' in HSPA8

The "METTL21A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL21A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets